Table 1.
Analysis of demographic variables.
| Variable | Schizophrenia spectrum disorders (n= 148) | Bipolar disorder (n= 104) | Combined sample (n= 252) |
|---|---|---|---|
| Age (years ± s.d) | 44.8 ± 11.7 | 42.7 ± 12.0 | 43.9 ± 11.9 |
| % Male* | 66 | 35 | 53 |
| % Caucasian/% African American* | 61/30 | 84/11 | 71/22 |
| % On Atypical Antipsychotics* | 83 | 70 | 78 |
| % On Clozapine or Olanzapine/% On Risperidone, Quetiapine, Iloperidone or Paliperidone* | 28/37 | 15/56 | 23/43 |
| % On Statins | 19 | 18 | 19 |
| % Smoking* | 49 | 32 | 42 |
| % With ATP III/NCEP Metabolic Syndrome | 30 | 26 | 29 |
| BMI (kg/m2± s.d.) | 31.4 ± 7.15 | 32.1 ± 8.88 | 31.7 ± 7.9 |
| Blood pressure (mmHg ± s.d.) | 122/75 ± 16/12 | 124/73 ± 18/11 | 123/74 ± 17/11 |
| Total cholesterol (mg/dL ± s.d.)* | 176 ± 39.2 | 192 ± 44.7 | 182 ± 42.2 |
| Triglycerides (mg/dL ± s.d.) | 131 ± 89.3 | 138 ± 104 | 134 ± 95.7 |
| High‐density lipoprotein (mg/dL ± s.d)* | 52.7 ± 16.3 | 58 ± 14.9 | 54.9 ± 15.9 |
| Low‐density lipoprotein (mg/dL ± s.d.)* | 108 ± 30.6 | 118 ± 38.2 | 112 ± 34.3 |
| Insulin (mU/L ± s.d.) | 22.9 ± 15.2 | 24.2 ± 20.8 | 23.5 ± 17.7 |
| Glucose (mg/dL ± s.d.) | 96.1 ± 12.5 | 96.0 ± 12.0 | 96.0 ± 12.3 |
| HbA1C% | 5.63 | 5.55 | 5.60 |
| HOMA‐IR ± s.d. | 5.51 ± 3.92 | 5.91 ± 5.46 | 5.68 ± 4.62 |
| % BDNF Val66Met Genotype (%) | 73 ValVal/24 ValMet/3 MetMet | 77 ValVal/20 ValMet/3 MetMet | 74 ValVal/23 ValMet/3 MetMet |
| % With BDNF 66Met Allele | 28 | 23 | 26 |
*Indicates p < 0.05 when comparing the Schizophrenia and Bipolar samples.